Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study)

@inproceedings{Peball2019NabiloneFN,
  title={Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study)},
  author={Marina Peball and Mario Werkmann and Philipp Ellmerer and Raphaela Stolz and Dora Valent and Hans-Guenther Knaus and Hanno Ulmer and Atbin Djamshidian and Werner Poewe and Klaus Seppi},
  booktitle={Journal of Neural Transmission},
  year={2019}
}
Although open-label observations report a positive effect of cannabinoids on non-motor symptoms (NMS) in Parkinson’s disease (PD) patients, these effects remain to be investigated in a controlled trial for a broader use in NMS in PD patients. Therefore, we decided to design a proof-of-concept study to assess the synthetic cannabinoid nabilone for the treatment of NMS. We hypothesize that nabilone will improve NMS in patients with PD and have a favorable safety profile. The NMS-Nab Study is as a… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 53 REFERENCES

: an in vivo microdialysis study

  • LR Mursaleen, JA Stamford
  • 2016
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Drugs of abuse and Parkinson's disease

VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity

VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Parkinson's disease

VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

The endocannabinoid system as an emerging target of pharmacotherapy.

VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

CB1 cannabinoid receptor signalling in Parkinson's disease.

VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review

2017) Parkinson disease

  • W Poewe
  • Nat Rev Dis Primers 3:17013
  • 2017